Table 3.
Cytogenetic Features and Risk Groups of Patients With MDS/CMML and AML
| Cytogenetic Finding | XRT (n = 47) |
C/CMT (n = 181) |
P (XRT v C/CMT) | De Novo (n = 222) |
P (XRT v De Novo) | |||
|---|---|---|---|---|---|---|---|---|
| No. | % | No. | % | No. | % | |||
| Karyotype | ||||||||
| Normal | 20 | 43 | 26 | 14 | < .001 | 99 | 45 | 1.0 |
| Abnormal | 24 | 51 | 150 | 83 | 113 | 51 | ||
| NA | 3 | 6 | 5 | 3 | 10 | 5 | ||
| Abnormalities of chromosomes 5 and 7 | ||||||||
| Deletion/loss of 5 | 9 | 19 | 95 | 52 | < .001 | 38 | 17 | .8 |
| Deletion/loss of 7 | 9 | 19 | 92 | 51 | < .001 | 35 | 16 | .5 |
| Deletion/loss of 5 or 7 | 12 | 26 | 115 | 63 | < .001 | 50 | 23 | .7 |
| AML cytogenetic risk group (UKMRC, AML only) | 21 | 61 | .03 (fav/int v adverse) | 119 | 1.0 (fav/int v adverse) | |||
| Favorable | 2 | 10 | 1 | 2 | .01 (fav/int v adv/11q23) | 17 | 14 | .8 (fav/int v adv/11q23) |
| Intermediate* | 10 | 48 | 16 | 26 | 58 | 49 | ||
| Adverse* | 6 | 29 | 33 | 54 | 37 | 31 | ||
| 11q23 rearrangement | 1 | 5 | 11 | 18 | 2 | 2 | ||
| Unknown | 2 | 10 | 0 | 5 | 4 | |||
| MDS cytogenetic risk group (IPSS, MDS/CMML only) | 26 | 120 | < .001 | 103 | .8 | |||
| Good | 17 | 65 | 14 | 12 | 67 | 65 | ||
| Intermediate | 4 | 15 | 15 | 12 | 11 | 11 | ||
| Poor | 4 | 15 | 86 | 72 | 20 | 19 | ||
| Unknown | 1 | 4 | 5 | 4 | 5 | 5 | ||
NOTE. All are two-sided Fisher's exact test.
Abbreviations: AML, acute myeloid leukemia; C/CMT, cytotoxic chemotherapy/combined-modality therapy; CMML, chronic myelomonocytic leukemia; fav, favorable; int, intermediate; IPSS, International Prognostic Scoring System; MDS, myelodysplastic syndrome; NA, not available; UKMRC, United Kingdom Medical Research Council; XRT, external-beam radiation therapy.
*
Excluding cases with 11q23 (MLL) rearrangement.